Ingalls & Snyder LLC Has $653,000 Stake in GSK plc (NYSE:GSK)

Ingalls & Snyder LLC reduced its position in shares of GSK plc (NYSE:GSK - Free Report) by 30.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,315 shares of the pharmaceutical company's stock after selling 8,340 shares during the period. Ingalls & Snyder LLC's holdings in GSK were worth $653,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GSK. Creative Planning raised its stake in GSK by 3.9% during the 3rd quarter. Creative Planning now owns 211,100 shares of the pharmaceutical company's stock valued at $8,630,000 after purchasing an additional 7,854 shares during the last quarter. Good Life Advisors LLC grew its holdings in GSK by 90.1% during the 3rd quarter. Good Life Advisors LLC now owns 14,486 shares of the pharmaceutical company's stock worth $592,000 after acquiring an additional 6,864 shares during the last quarter. Global Retirement Partners LLC grew its holdings in GSK by 4.3% during the 3rd quarter. Global Retirement Partners LLC now owns 40,110 shares of the pharmaceutical company's stock worth $1,640,000 after acquiring an additional 1,664 shares during the last quarter. Cardinal Capital Management grew its holdings in GSK by 1.5% during the 3rd quarter. Cardinal Capital Management now owns 56,372 shares of the pharmaceutical company's stock worth $2,326,000 after acquiring an additional 808 shares during the last quarter. Finally, Aaron Wealth Advisors LLC grew its position in shares of GSK by 11.3% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 20,711 shares of the pharmaceutical company's stock worth $847,000 after buying an additional 2,103 shares during the period. 15.74% of the stock is owned by institutional investors.

GSK Stock Down 1.0 %

Shares of GSK stock traded down $0.36 during trading on Monday, reaching $36.20. The company's stock had a trading volume of 4,541,918 shares, compared to its average volume of 4,879,423. The business has a fifty day moving average price of $34.42 and a 200-day moving average price of $37.44. The company has a quick ratio of 0.53, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The company has a market cap of $75.02 billion, a price-to-earnings ratio of 22.76, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. GSK plc has a one year low of $31.72 and a one year high of $45.92.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Analysts anticipate that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.34%. The ex-dividend date is Friday, February 21st. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is currently 93.08%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, Jefferies Financial Group lowered shares of GSK from a "buy" rating to a "hold" rating and cut their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.